Hims & Hers Stock Tumbles as Gross Margin Woes Overshadow 49% Revenue Growth
Read source articleWhat happened
Hims & Hers Health posted 49% revenue growth in its latest quarter, but the market focused on a net loss driven by deteriorating gross margins, sending shares sharply lower. The company's shift toward branded GLP-1 weight-loss drugs has boosted revenue per subscriber but crushed profitability, with gross margin falling from 76% a year ago to around 64% in Q2 2026 and remaining under pressure. Management's guidance suggests near-term margins will stay below prior-year levels, while elevated customer acquisition costs and a pending FTC lawsuit add uncertainty to the growth story. The stock's decline reflects investors pricing in that the current high-growth model lacks durable unit economics, despite strong demand and rising deferred revenue. While liquidity remains robust at over $840M, the valuation still embeds a recovery that has not yet been proven.
Implication
If Q4 2026 shows gross margin rebounding above 66% and adjusted EBITDA margin holding at 10% or higher, the current selloff could be a buying opportunity. However, if margins stay near 64% or the FTC case results in operational restrictions, the stock could face further downside toward the bear-case value of $22. Investors should monitor subscriber retention, CAC efficiency, and legal accruals in the next quarterly reports before committing fresh capital.
Thesis delta
The thesis remains a WAIT. Today's earnings confirm that revenue growth is strong but margin compression is a persistent problem; the core question is whether the branded GLP-1 membership model can restore profitability. The news does not change our fundamental view, but it reinforces the need for proof of operating leverage before considering a long position.
Confidence
Medium